CP-690550

• CAT Number: A000725
• CAS Number: 477600-75-2
• Molecular Formula: C16H20N6O
• Molecular Weight: 312.37
• Purity: ≥95%
• Synonyms: Tofacitinib base;CP-690550;Tasocitinib
• Target: JAK
• Solubility: Soluble in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
• InChI: InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1
• InChIKey: UJLAWZDWDVHWOW-YPMHNXCESA-N
• SMILES: C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N

CP-690550(Cat No.:A000725), also known as Tofacitinib, is an oral Janus kinase (JAK) inhibitor used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by inhibiting the JAK-STAT signaling pathway, which plays a crucial role in the immune response and inflammation. By blocking this pathway, Tofacitinib reduces inflammation and immune system activity, alleviating symptoms of these chronic diseases. It is effective in improving joint function and slowing disease progression. Common side effects include infections, elevated liver enzymes, and lipid levels. Regular monitoring is necessary to manage potential risks.